On February 27, 2026, during an appearance on the Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. announced that many currently restricted peptides are expected to move back to Category 1 status. If formally updated by the U.S. Food and Drug Administration, this would allow licensed U.S. compounding pharmacies to legally prepare these peptides again with a valid prescription. For patients who value medically guided peptide therapy, this is meaningful news and new peptides may be available soon.
How We Got Here
Between late 2023 and 2024, the FDA reclassified 19 commonly compounded peptides from Category 1 (eligible for compounding) to Category 2 (flagged for potential safety concerns).
Category 2 placement effectively stopped compounding pharmacies from preparing them, even for patients who had been using these therapies responsibly under physician supervision.
The agency cited concerns about limited human safety data and immunogenicity. However, a legal challenge argued that the required safety threshold to justify the restriction had not been met.
According to RFK Jr.’s recent statement, that review process is now reversing course for most of those peptides.
What Category 1 Actually Means
If these peptides return to Category 1:
-
Licensed 503A and 503B compounding pharmacies may legally prepare them
-
A prescription from a licensed clinician is still required
-
Pharmacies must comply with USP 795/797 quality standards
-
Products must come from regulated pharmaceutical suppliers
This does not mean the peptides are FDA-approved drugs. Full FDA approval requires large clinical trials demonstrating safety and efficacy for specific medical indications. Category 1 status simply restores legal compounding access under medical supervision.
Why This Matters for Patients
When the 19 peptides were restricted, demand did not disappear.
Instead, many individuals turned to:
-
Overseas suppliers
-
“Research use only” vendors
-
Online gray-market platforms
Those products often lack sterility testing, purity verification, and proper dosing controls. Contamination and mislabeling risks are real.
As RFK Jr. acknowledged publicly, restricting regulated access may have unintentionally pushed patients toward unregulated alternatives.
If compounding eligibility is restored, patients can return to physician-supervised, pharmaceutical-grade channels — which is always the safer path.
Peptides Likely to Return
While official FDA publication is still pending, peptides discussed in the announcement include several widely used compounds in regenerative and metabolic medicine, such as:
-
Thymosin Alpha-1
-
AOD-9604
-
Selank
-
Semax
-
KPV
-
MOTS-C
-
GHK-Cu
Some peptides with more concerning safety profiles may remain restricted. We are closely monitoring formal FDA updates before adjusting any protocols.
What This Means at Flow Wellness
At Flow Wellness, we have always approached peptide therapy through a medical lens:
-
Comprehensive consultation
-
Baseline labs when appropriate
-
Individualized treatment plans
-
Ongoing monitoring
-
Pharmaceutical-grade sourcing
We do not support gray-market purchasing or unsupervised peptide use.
If these peptides officially return to Category 1 status, licensed compounding pharmacies may resume legal preparation under prescription. If they do not, we will continue to adapt responsibly within regulatory guidelines.
Our commitment does not change with headlines.
We prioritize safety, compliance, and thoughtful clinical decision-making — not shortcuts.
What You Should Do Now
There is no need to rush or stockpile.
Until the FDA formally updates its guidance:
-
Avoid purchasing peptides from unregulated sources
-
Continue working with licensed medical providers
-
Wait for confirmed regulatory publication
When changes become official, we will communicate clearly with our patients and discuss whether peptide therapy is appropriate for your goals.
Looking Ahead
Peptide medicine continues to evolve. Regulation is part of that evolution.
If several of the above peptides return to legal compounding status, this represents a shift back toward structured, physician-guided access rather than gray-market alternatives.
For patients focused on metabolic health, recovery, immune balance, and performance optimization, clarity and medical oversight matter more than ever.
At Flow Wellness in Bend, Oregon and Seattle, Washington, we will continue guiding patients through these changes with transparency and evidence-informed care.
Healthcare evolves. Innovation continues. And when new peptides become available soon, they should be introduced responsibly — with medical supervision at the center.
Schedule a peptide consultation
